Advertisement

The Protein Journal

, Volume 32, Issue 6, pp 456–466 | Cite as

Improved Protease Stability of the Antimicrobial Peptide Pin2 Substituted with d-Amino Acids

  • G. Carmona
  • A. Rodriguez
  • D. Juarez
  • G. Corzo
  • E. Villegas
Article

Abstract

Cationic antimicrobial peptides (AMPs) have attracted a great interest as novel class of antibiotics that might help in the treatment of infectious diseases caused by pathogenic bacteria. However, some AMPs with high antimicrobial activities are also highly hemolytic and subject to proteolytic degradation from human and bacterial proteases that limit their pharmaceutical uses. In this work a d-diastereomer of Pandinin 2, d-Pin2, was constructed to observe if it maintained antimicrobial activity in the same range as the parental one, but with the purpose of reducing its hemolytic activity to human erythrocytes and improving its ability to resist proteolytic cleavage. Although, the hydrophobic and secondary structure characteristics of l- and d-Pin2 were to some extent similar, an important reduction in d-Pin2 hemolytic activity (30–40 %) was achieved compared to that of l-Pin2 over human erythrocytes. Furthermore, d-Pin2 had an antimicrobial activity with a MIC value of 12.5 μM towards Staphylococcus aureus, Escherichia coli, Streptococcus agalactiae and two strains of Pseudomonas aeruginosa in agar diffusion assays, but it was half less potent than that of l-Pin2. Nevertheless, the antimicrobial activity of d-Pin2 was equally effective as that of l-Pin2 in microdilution assays. Yet, when d- and l-Pin2 were incubated with trypsin, elastase and whole human serum, only d-Pin2 kept its antimicrobial activity towards all bacteria, but in diluted human serum, l- and d-Pin2 maintained similar peptide stability. Finally, when l- and d-Pin2 were incubated with proteases from P. aeruginosa DFU3 culture, a clinical isolated strain, d-Pin2 kept its antibiotic activity while l-Pin2 was not effective.

Keywords

d-diastereomer Peptide Antimicrobial Hemolysis Enzyme degradation 

Abbreviations

RP-HPLC

Reverse-phase HPLC

HPLC

High pressure liquid chromatography

MHB

Mueller–Hinton broth

MHA

Mueller–Hinton agar

CFU

Colony forming units

CD

Circular dichroism

AMP

Cationic antimicrobial peptide

MIC

Minimal inhibitory concentrations

TFA

Trifluoroacetic acid

PBS

Phosphate buffer saline, pH 7.2

PAGE

Polyacrylamide gel electrophoresis

SDS

Sodium dodecyl sulfate

TFE

2,2,2-trifluoroethanol

Notes

Acknowledgments

We acknowledge Dr. Fernando Zamudio for mass spectrometric determinations and QBP Ma. Rocio Patiño Maya for CD spectra data acquisition. Gabriela Carmona was recipient of an MSc scholarship 30175 from CONACyT (226330). Daniel Juaréz was recipient of an undergraduate scholarship from RedFarmed-CONACyT. Alexis Rodríguez was recipient of a PhD scholarship 24492 from CONACyT (172816), and now he is supported by a postdoctoral fellowship from PROMEP. This work was also supported by CONACyT proyect Grants 153606 to GC, and 83962/2007 and 106949/2008 to Elba Villegas.

Supplementary material

10930_2013_9505_MOESM1_ESM.tif (5 mb)
Mass spectra of L-Pin2 (A) D-Pin2 (B). (TIFF 5082 kb)
10930_2013_9505_MOESM2_ESM.tif (545 kb)
Zymogram of proteases from P. aeruginosa strains ATCC 27853 and DFU3. On the right side, the first four lanes of the gel correspond to the proteins from the supernatant from a culture of P. aeruginosa strains ATCC 27853. The following four lanes in the same gel correspond to the proteins from the supernatant from a culture of P. aeruginosa strains DFU3. On the left side, the molecular weight markers are shown. (TIFF 544 kb)
10930_2013_9505_MOESM3_ESM.tif (3.1 mb)
Twenty-four N-terminal degradation cycles of D-Pin2. Reverse-phase HPLC chromatograms of each phenylthiohydantoin (PTH)-amino acid. The magenta profile represents the separation of the PTH-amino acid from the N-terminal degradation of D-Pin2, and the black profile represents PTH-L-amino acid standards. Some HPLC chromatograms were zoomed into observe in detail the eluting peaks. The cycle 01 contains also a peak that elutes within the Gln elution time as a consequence of the polybrene reaction. DMPTU, the peak at 8.5 min and DPTU are secondary products of the N-terminal reaction. (TIFF 3128 kb)
10930_2013_9505_MOESM4_ESM.tif (3.1 mb)
Stability of D-Pin2 in the presence of trypsin and elastase. After enzyme treatment (4 h) with either trypsin (A) and elastase (B) (see Materials and methods), D-Pin2 was separated using an analytical reverse phase C18 column, at a flow rate of 1 mL/min, with linear gradients from 15-60 % B in 45 min (TIFF 3128 kb)
10930_2013_9505_MOESM5_ESM.tif (104 kb)
Stability of D-Pin2 in the presence of Pseudomonas aeruginosa DFU3 proteases. D-Pin2 was incubated in the presence of P. aeruginosa DFU3 proteases. Samples were taken at 0, 4, 8, 12 and 24 h (A, B, C, D and E, respectively) and separated using an analytical reverse phase C18 column, at a flow rate of 1 mL/min, with linear gradients from 15-60 % B in 45 min (absorbance at A230). (TIFF 104 kb)

References

  1. 1.
    Andrade MA, Chacón P, Merelo JJ, Morán F (1993) Prot Eng 6:383–390CrossRefGoogle Scholar
  2. 2.
    Andreu D, Rivas L (1998) Biopolymers 47:415–433CrossRefGoogle Scholar
  3. 3.
    Badosa E, Ferre R, Planas M, Feliu L, Besalu E, Cabrefiga J, Bardaji E, Montesinos E (2007) Peptides 28:2276–2285CrossRefGoogle Scholar
  4. 4.
    Barrera-Juanchi J, Barrios-Casarrubias A, Arcos-Aponte ME, Saldaña de Jesus N (2007) Bioquimia 32:SuA1Google Scholar
  5. 5.
    Belokoneva OS, Villegas E, Corzo G, Dai L, Nakajima T (2003) Biochim Biophys Acta 1617:22–30CrossRefGoogle Scholar
  6. 6.
    Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M (1990) FEBS Lett 274:151–155CrossRefGoogle Scholar
  7. 7.
    Bland JM, De Lucca AJ, Jacks TJ, Vigo CB (2001) Mol Cell Biochem 218:105–111CrossRefGoogle Scholar
  8. 8.
    Bulet P, Hetru C, Dimarcq JL, Hoffmann D (1999) Dev Comp Immunol 23:329–344CrossRefGoogle Scholar
  9. 9.
    Caballero AR, Moreau JM, Engel LS, Marquart ME, Hill JM, O’Callaghan RJ (2001) Anal Biochem 290:330–337CrossRefGoogle Scholar
  10. 10.
    Cava F, Lam H, de Pedro MA, Waldor MK (2011) Cell Mol Life Sci 68:817–831CrossRefGoogle Scholar
  11. 11.
    Chen Y, Vasil AI, Rehaume L, Mant CT, Burns JL, Vasil ML, Hancock RE, Hodges RS (2006) Chem Biol Drug Des 67:162–173CrossRefGoogle Scholar
  12. 12.
    CLSI CaLSI (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Standards NCCL (ed) NCCLS document M07-A6. Wayne, National Committee for Clinical Laboratory StandardsGoogle Scholar
  13. 13.
    CLSI CaLSI (2009) Performance standards for antimicrobial susceptibility testing In: Standards NCCL (ed) NCCLS document M100-S19. Wayne, National Committee for Clinical Laboratory StandardsGoogle Scholar
  14. 14.
    CLSI CaLSI (2011) Performance standards for antimicrobial susceptibility testing. In: Standards NCCL (ed) NCCLS document 31M100—S21. Wayne, National Committee for Clinical Laboratory StandardsGoogle Scholar
  15. 15.
    Conlon JM, Al-Ghaferi N, Abraham B, Leprince J (2007) Methods 42:349–357CrossRefGoogle Scholar
  16. 16.
    Corzo G, Escoubas P, Villegas E, Barnham KJ, He W, Norton RS, Nakajima T (2001) Biochem J 359:35–45CrossRefGoogle Scholar
  17. 17.
    Dean SN, Bishop BM, van Hoek ML (2011) BMC Microbiol 11:114CrossRefGoogle Scholar
  18. 18.
    Elmquist A, Langel U (2003) Biol Chem 384:387–393CrossRefGoogle Scholar
  19. 19.
    Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, Lelli B, Bindi S, Scali S, Di Giulio A, Rossolini GM, Mangoni ML, Bracci L, Pini A (2012) PLoS ONE 7:e46259CrossRefGoogle Scholar
  20. 20.
    Guell I, Cabrefiga J, Badosa E, Ferre R, Talleda M, Bardaji E, Planas M, Feliu L, Montesinos E (2011) Appl Environ Microbiol 77:2667–2675CrossRefGoogle Scholar
  21. 21.
    Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K (2002) Microbiol Immunol 46:741–749Google Scholar
  22. 22.
    Hong J, Oren Z, Shai Y (1999) Biochemistry 38:16963–16973CrossRefGoogle Scholar
  23. 23.
    Hong SY, Oh JE, Lee KH (1999) Biochem Pharmacol 58:1775–1780CrossRefGoogle Scholar
  24. 24.
    Hung LW, Kohmura M, Ariyoshi Y, Kim SH (1998) Acta Crystallogr D Biol Crystallogr 54:494–500CrossRefGoogle Scholar
  25. 25.
    Jiang Z, Higgins MP, Whitehurst J, Kisich KO, Voskuil MI, Hodges RS (2011) Protein Pept Lett 18:241–252CrossRefGoogle Scholar
  26. 26.
    Kamysz W (2005) Nucl Med Rev Cent East Eur 8:78–86Google Scholar
  27. 27.
    Kuhn-Nentwig L (2003) Cell Mol Life Sci 60:2651–2668CrossRefGoogle Scholar
  28. 28.
    Lee J, Lee DG (2010) J Microbiol Biotechnol 20:1192–1195CrossRefGoogle Scholar
  29. 29.
    Matsuzaki K (2009) Biochim Biophys Acta 1788:1687–1692CrossRefGoogle Scholar
  30. 30.
    McCarter JD, Stephens D, Shoemaker K, Rosenberg S, Kirsch JF, Georgiou G (2004) J Bacteriol 186:5919–5925CrossRefGoogle Scholar
  31. 31.
    Merelo JJ, Andrade MA, Prieto A, Morán F (1994) Neurocomputing 6:443–454CrossRefGoogle Scholar
  32. 32.
    Moncla BJ, Pryke K, Rohan LC, Graebing PW (2011) Adv Biosci Biotechnol 2:404–408CrossRefGoogle Scholar
  33. 33.
    Nan YH, Bang JK, Shin SY (2009) Peptides 30:832–838CrossRefGoogle Scholar
  34. 34.
    Nomura K, Corzo G, Nakajima T, Iwashita T (2004) Biophys J 87:2497–2507CrossRefGoogle Scholar
  35. 35.
    Oldak E, Trafny EA (2005) Antimicrob Agents Chemother 49:3281–3288CrossRefGoogle Scholar
  36. 36.
    Oren Z, Shai Y (1997) Biochemistry 36:1826–1835CrossRefGoogle Scholar
  37. 37.
    Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC (2000) Proc Natl Acad Sci USA 97:8245–8250CrossRefGoogle Scholar
  38. 38.
    Pathak N, Salas-Auvert R, Ruche G, Janna MH, McCarthy D, Harrison RG (1995) Proteins 22:182–186CrossRefGoogle Scholar
  39. 39.
    Potempa J, Dubin A, Korzus G, Travis J (1988) J Biol Chem 263:2664–2667Google Scholar
  40. 40.
    Rodriguez A, Villegas E, Satake H, Possani LD, Corzo G (2011) Amino Acids 40:61–88CrossRefGoogle Scholar
  41. 41.
    Shai Y, Oren Z (2001) Peptides 22:1629–1641CrossRefGoogle Scholar
  42. 42.
    Shanmugam P (2013) M J, Susan SL. J Clin Diagn Res 7:441–445Google Scholar
  43. 43.
    Sonnichsen FD, Van Eyk JE, Hodges RS, Sykes BD (1992) Biochemistry 31:8790–8798CrossRefGoogle Scholar
  44. 44.
    Wade D, Boman A, Wahlin B, Drain CM, Andreu D, Boman HG, Merrifield RB (1990) Proc Natl Acad Sci USA 87:4761–4765CrossRefGoogle Scholar
  45. 45.
    Wakabayashi H, Matsumoto H, Hashimoto K, Teraguchi S, Takase M, Hayasawa H (1999) Antimicrob Agents Chemother 43:1267–1269Google Scholar
  46. 46.
    Wei G, de Leeuw E, Pazgier M, Yuan W, Zou G, Wang J, Ericksen B, Lu WY, Lehrer RI, Lu W (2009) J Biol Chem 24:29180–29192CrossRefGoogle Scholar
  47. 47.
    Yadav SJ, Chowdhury S, Chaudhuri SR (2010) J Biol Sci 10:424–431CrossRefGoogle Scholar
  48. 48.
    Yanmei L, Hongyan Q, Qi X, Zhijian S, Yadong H, Zhijian S (2012) Peptides 37:2207–2215Google Scholar
  49. 49.
    Yeaman MR, Yount NY (2003) Pharmacol Rev 55:27–55CrossRefGoogle Scholar
  50. 50.
    Zhu WL, Nan YH, Hahm KS, Shin SY (2007) J Biochem Mol Biol 40:1090–1094CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • G. Carmona
    • 1
  • A. Rodriguez
    • 1
  • D. Juarez
    • 1
  • G. Corzo
    • 2
  • E. Villegas
    • 1
  1. 1.Laboratorio de Estructura-Funcion e Ingenieria de ProteinasCentro de Investigacion en Biotecnologia Universidad Autonoma del Estado de MorelosCuernavacaMexico
  2. 2.Departamento de Medicina Molecular y BioprocesosInstituto de Biotecnologia, UNAMCuernavacaMexico

Personalised recommendations